Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity

Context: Bacillus Calmette-Guerin (BCG) therapy is the standard treatment for nonmuscle-invasive bladder cancer (NMIBC). However, its toxicity is a major concern. Aim: If we reduce the number of BCG doses by half and replace the second half with epirubicin, we may have a lower toxicity while mainta...

Full description

Bibliographic Details
Main Authors: Bedeir Ali-El-Dein, Tamer S Barakat, Adel Nabeeh, El-Housseiny I Ibrahiem
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Urology Annals
Subjects:
Bacillus Calmette-Guerin
epirubicin
nonmuscle-invasive bladder cancer
Ta
T1
toxicity
Online Access:http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=2;spage=103;epage=108;aulast=Ali-El-Dein

Internet

http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=2;spage=103;epage=108;aulast=Ali-El-Dein

Similar Items